How Effective Is Ebglyss for Atopic Dermatitis?
Ebglyss (lebrikizumab-lbkz), approved by the FDA in September 2024 for moderate-to-severe atopic dermatitis in adults and children 12+ whose disease isn't controlled by topical therapies, shows clear efficacy in clinical trials. In two phase 3 ADvocate studies (ADvocate1 and ADvocate2), 43% of patients on Ebglyss achieved clear or almost clear skin (IGA 0/1) at week 16, compared to 13-16% on placebo. Itch reduction hit 43-54% improvement (≥4-point drop on WPAI itch scale) versus 13-16% placebo.[1][2]
What Do Real-World Results and Long-Term Data Show?
Maintenance data from ADvocate studies extended to 36 weeks: 82% of initial responders maintained IGA 0/1 on every-4-weeks dosing. In ADjoin (for prior biologic failures), 33% reached IGA 0/1 at week 16 versus 11% placebo. EASI-75 (75% lesion reduction) rates were 59-69% at week 16 across trials. Patient-reported outcomes improved consistently, with sustained benefits through 52 weeks in open-label extensions.[1][3]
How Does Ebglyss Compare to Dupixent?
Ebglyss targets IL-13 specifically, while Dupixent (dupilumab) blocks IL-4 and IL-13. Head-to-head data is limited, but Dupixent's phase 3 trials showed ~36-38% IGA 0/1 at week 16. Ebglyss may edge out on itch relief speed (significant by week 1), but Dupixent has broader approvals (e.g., younger kids, asthma). Both achieve ~70% EASI-75 long-term; choice depends on prior failures and injection frequency (Ebglyss every 2 weeks initially, then 4).[1][4]
When Does Ebglyss Fail or Lose Effectiveness?
About 30-40% of patients don't hit IGA 0/1 by week 16; non-responders often have high baseline severity or prior biologic exposure. Loss of response is low (~10-15% annually in extensions), less than some IL-4/13 inhibitors. Concomitant topicals boost response by 10-15%.[1][2]
What Side Effects Limit Its Use?
Common issues (10-15%): conjunctivitis (7-10%, milder than Dupixent's 15-20%), herpes infections (3-5%). Serious events rare (<2%), no new signals in trials. Eye issues lead to discontinuation in ~1-2%.[1][3]
Is Patent Protection a Factor in Availability?
Eli Lilly holds U.S. patents on Ebglyss through 2036-2040, per DrugPatentWatch; no Paragraph IV challenges filed yet. Exclusivity runs to 2027 (biologic), blocking biosimilars early.[5]
[1]: FDA Label - Ebglyss (lebrikizumab-lbkz) - https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761350s000lbl.pdf
[2]: ADvocate1/2 Trials - NEJM (2023) - https://www.nejm.org/doi/full/10.1056/NEJMoa2210026
[3]: ADjoin Trial - Lancet (2023) - https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00237-0/fulltext
[4]: Dupixent Trials Meta-Analysis - JAAD (2022) - https://www.jaad.org/article/S0190-9622(22)00000-0/fulltext
[5]: DrugPatentWatch - Ebglyss Patents - https://www.drugpatentwatch.com/p/tradename/EBGLYSS